Resources for PrEP users
This website and specific webpage is intended for UK healthcare professionals only. The below resources are intended to support patients who have been prescribed APRETUDE.
APRETUDE Welcome Video
Equipping PrEP users with the necessary information they need to start their APRETUDE journey.
PrEP, pre-exposure prophylaxis.
References:
- APRETUDE (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC)
- New cabotegravir formulations approved to help prevent HIV-1 infection in adults and adolescents, GOV.UK. Available at: https://www.gov.uk/government/news/new-cabotegravir-formulations-approved-to-help-prevent-hiv-1-infection-in-adults-and-adolescents. Accessed January 2025.
PM-GB-CBT-WCNT-240007 February 2025
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
